Description

Irinotecan Vista for Infusions 20 mg/ml. 5 ml/100 mg Vial

Ingredients:

Irinotecan Vista contains irinotecan hydrochloride trihydrate as the active ingredient.

Dosage:

The recommended dosage of Irinotecan Vista for infusion is determined by a healthcare provider based on individual factors such as body surface area and the specific condition being treated.

Indications:

Irinotecan Vista is indicated for the treatment of colorectal cancer and other solid tumors.

Contraindications:

Irinotecan Vista is contraindicated in patients with a known hypersensitivity to irinotecan or any of the excipients in the formulation.

Directions:

Irinotecan Vista should be administered by a healthcare professional experienced in the use of cancer chemotherapeutic agents.

Scientific Evidence:

Studies have shown that Irinotecan Vista, when used in combination with other chemotherapy agents, can significantly improve progression-free survival in patients with advanced colorectal cancer.

Additional Information:

It is important to monitor patients receiving Irinotecan Vista for signs of neutropenia, diarrhea, and other potential adverse reactions.

Pharmacological Effects: Irinotecan Vista is a topoisomerase I inhibitor that interferes with DNA replication and cell division, ultimately leading to cell death. It is an important component of many chemotherapy regimens for solid tumors.

Clinical Trials: Clinical trials have demonstrated the efficacy of Irinotecan Vista in improving overall survival rates and quality of life in patients with advanced colorectal cancer. These studies have highlighted the importance of Irinotecan Vista in the treatment of certain types of cancer.